Halozyme To Acquire Antares Pharma To Create A Specialty Product And Drug Delivery Leader
Acquiring Company
Halozyme Therapeutics
Acquired Company
Antares Pharma
San DiegoManufacturingBiotechnologyHealth CarePharmaceuticalBiopharmaManufacturingBiotechnologyHealth CareScience And EngineeringDescription
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") and Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") today announced that the companies have entered into a definitive agreement pursuant to which Halozyme will acquire Antares for $5.60 per share in cash. The transaction, which values Antares at approximately $960 million, was unanimously approved by both the Halozyme and Antares Boards of Directors.
Quick answer
Halozyme Therapeutics is acquiring Antares Pharma, announced April 13, 2022. Halozyme Therapeutics is based in San Diego, California, United States.
- How much did Halozyme Therapeutics pay for Antares Pharma?
- The deal value was not disclosed.
- What does Halozyme Therapeutics do?
- Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.
- Where are Halozyme Therapeutics and Antares Pharma based?
- Halozyme Therapeutics is based in San Diego, California, United States.
- Who are the decision-makers at Halozyme Therapeutics?
- Fundz holds 3 contacts at Halozyme Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Pharmaceutical and Biopharma
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Halozyme Completes Antares Pharma Acquisition (May 24, 2022)
- Hikma Completes Acquisition Of Custopharm (April 21, 2022)
- Aprea Therapeutics Announces Acquisition Of Atrin Pharmaceuticals Inc. And Reports First Quarter 2022 Financial Results (May 16, 2022)
- Pfizer To Acquire Biohaven Pharmaceuticals (May 10, 2022)
- Regeneron To Acquire Checkmate Pharmaceuticals And Its Investigational Immune Activator For Potential Use In Multiple Tumor Types (April 19, 2022)
- Consegna Pharma Acquires Fathom Pharma To Strengthen Initiatives That Address The Opioid Crisis (April 19, 2022)
Who to call at Halozyme Therapeutics, and when
When Halozyme Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Halozyme Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Halozyme Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Halozyme Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Halozyme Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Antares Pharma?
Antares Pharma was acquired by Halozyme Therapeutics, based in San Diego. The deal was reported on April 13, 2022. Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. Halozyme Therapeutics is publicly traded (HALO) and operates in Manufacturing.
When did Halozyme Therapeutics acquire Antares Pharma?
Halozyme Therapeutics's acquisition of Antares Pharma was reported on April 13, 2022. Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") and Antares Pharma, Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Antares Pharma do?
Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It is privately held, operating in Manufacturing.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.